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“gold standard”, were set at 100%, while ranges for sensitivity
and speciﬁcity for MRA were drawn from literature and used
for sensitivity analysis. Analyses performed for a hypothetical
population of 91,665 (US diabetics with PAD who are eligible
for treatment in 2000) included: one-year total health care costs,
total Quality Adjusted Life Year Gained (QALYG; the increase
in quality of life after treatment), cost per QALYG, incremental
cost per QALY, and cost of accurate and inaccurate planning
with medical management, PTA, bypass, and amputation.
RESULTS: In the base-case scenario, with MRA sensitivity and
speciﬁcity at 98% and 83% respectively, the one-year per patient
total health care costs in the diabetic PAD population was
$20,176 for patients receiving an MRA versus $21,996 for those
receiving a DSA for treatment planning. The total QALYG were
higher in the MRA cohort than in the DSA cohort, 0.11 versus
0.07 respectively. Therefore, the total cost per QALYG was
$106,948 higher for patients who received a DSA ($190,697 vs.
$297,645). MRA dominates the DSA in incremental cost/QALY
with savings of $57,060, due to a lower risk of complication and
the resultant greater increase in QALYG and lower cost of treat-
ment. CONCLUSION: This model demonstrates that MRA as
a treatment-planning tool, with lower risk of complication, could
substantially reduce the cost and cost per quality-adjusted life
years for peripheral arterial disease in diabetic patients.
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OBJECTIVES: Nearly 600,000 patients are diagnosed with Deep
Vein Thrombosis (DVT) in US every year. One in every 100
patient dies due to pulmonary embolism developed as a later
complication. DVT during abdominal surgery is a frequent
problem & therefore prophylaxis is a compulsion. The objective
of this study was to identify the least costly prophylactic treat-
ment taking into account DVT complications from the health
care payer perspective. METHODS: Cost comparison was done
using a decision tree. The probabilities and costs for postopera-
tive DVT was obtained from clinical trial studies and other pub-
lished sources. Prophylaxis during surgery was considered to 
be for 9 days whereas treatment for postoperative DVT was
assumed to be for 5 days. Total cost included drug acquisition
cost, hospitalization costs for DVT. Expected value was com-
puted at each chance nodes. RESULTS: Fondaparinux sodium
has the least probability (0.042) for postoperative DVT compli-
cations whereas Enoxaparin sodium & unfractionated heparin
(UFH) have higher probabilities of 0.048 & 0.11 respectively.
The drug acquisition cost for prophylaxis was highest with fon-
daparinux sodium (2.5 mg) at $36.69, enoxaparin sodium (40
mg) at $24.74 & UFH (5000 IU) at $3.06 per single dose. Low
molecular weight heparins were given once daily while UFH was
given twice daily. Expected value was found to be $1129.720,
$1133.590 & $2256.730 for fondaparinux sodium, enoxaparin
sodium & UFH respectively. Sensitivity Analysis showed that the
model is somewhat inﬂuenced by adverse events & costs. CON-
CLUSION: Fondaparinux sodium has been found to have 
the least costly prophylactic treatment. Although the acquisition
cost is the highest, it is offset by the low probability of deve-
loping DVT complications and later hospitalization costs. UFH
even though having the lowest acquisition cost, has high rate 
of DVT complications & higher hospitalization cost due to 
frequent administration procedures & continuous monitoring
requirement.
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OBJECTIVES: To compare the costs resulting from a treatment
with ivabradine, a new medication for stable angina pectoris
patients, with standard care for those patients who cannot be
appropriately treated with standard medication in The Nether-
lands in 2006. METHODS: A decision analytic model was used
to estimate the cost-effectiveness of ivabradine in patients with
stable angina pectoris, who cannot be appropriately treated with
standard medication and are therefore currently candidates for
revacularisation (ESC guidelines 2006 on the management of
stable angina pectoris). Therefore ivabradine is compared with
standard care consisting of revascularization (CABG or PTCA).
The study was performed within the society perspective, which
included costs of medication and revascularisation procedures.
The data sources included published literature, the ivabradine
clinical trials, the Euro Heart Survey for stable angina, which
provided data from daily practice, and ofﬁcial price/tariff 
lists and national population statistics. RESULTS: Treatment
with ivabradine results in 77% reduction in revascularisation
and leads to a cost saving of €7028 per patient compared with
revacularisation during the ﬁrst year of treatment. Sensitivity
analyses showed that extrapolation beyond one year leads to
further cost savings. Another sensitivity analysis on the proba-
bility of revascularisation showed that cost savings vary from
€2882 to €9102. CONCLUSION: This model showed that the
use of ivabradine compares favourably with revascularisation in
treatment of stable angina pectoris in The Netherlands from a
budgetary and health economic perspective: the total costs are
substantially lower, whereas the effectiveness is at least similar.
Consequently ivabradine can be considered a cost-effective
treatment being dominant over standard care.
PCV21
ECONOMIC EVALUATION OF EPLERENONE COMPARED
WITH PLACEBO IN PATIENTS WITH MYOCARDIAL
INFARCTION COMPLICATED BY LEFT VENTRICULAR
SYSTOLIC DYSFUNCTION AND HEART FAILURE IN MEXICO
Mould-Quevedo J, Salomon-Molina A, Davila-Loaiza G
Pﬁzer Mexico, Mexico City, Mexico
OBJECTIVES: In Mexico in 2005, there are more than 250,000
patients in secondary prevention. One of the most serious and
frequent consequences of survivors of acute myocardial infarc-
tion (AMI) is heart failure, which is associated with a 55%
greater risk of dying and 2.15-times- greater risk of death or
recurrent AMI at 30 days. The purpose of this study was to 
evaluate the cost—effectiveness of eplerenone compared with
placebo from the Mexican health care payer’s perspective.
METHODS: We used a three-year analysis model to estimate
costs and effectiveness. Effectiveness measures were the num-
ber of life-year gained (LYG) and quality-adjusted life-years
(QALYs). Effectiveness data was obtained from the Eplerenone
Post-Acute Myocardial Infarction Heart Failure Efﬁcacy and
Survival Study (EPHESUS). Survival beyond the trial period (16
months) was estimated from data from the Framingham Heart
Study. The estimation of resource use was performed employing
local expert opinion surveys and they included hospitalization,
emergency room visits, outpatient services and medication. Costs
and life expectancy differences were discounted 5% annually.
Threshold sensitivity analysis was performed and acceptability
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curves were constructed. RESULTS: Eplerenone added incre-
mental beneﬁt on mortality and morbility above placebo. Costs
was $US1279.70 higher in the eplerenone treatment (CI 95%,
$US604-1992) because of the drug cost. For eplerenone versus
placebo, the incremental cost—effectiveness ratio (ICER) was
$US13,169.8 per LYG and $US19,753.4 per QALY gained.
Using a willingness-to-pay threshold of $US20,000 per LYG or
QALY gained, 64.3% of estimates fell below this threshold.
CONCLUSION: Eplerenone compared with placebo in the treat-
ment of heart failure after AMI is effective in reducing mortal-
ity and is cost—effective with a threshold of $US20.000 per LYG
in Mexico. These results should be taken into account by
Mexican decision makers and clinicians in the management of
patients with left ventricular systolic dysfunction and heart
failure following AMI.
PCV22
A CARDIOVASCULAR DISEASE COST-EFFECTIVENESS MODEL
BASED ON CTT META-ANALYSIS
Lundy J1, Davies GM2, Cook JR2
1University of Arizona,Tucson, AZ, USA, 2Merck and Co. Inc, North
Wales, PA, USA
OBJECTIVES: To evaluate the cost-effectiveness of lipid-lower-
ing therapy for cardiovascular disease based upon the event risk
and LDL-C reduction relationship observed in the Clinical Treat-
ment Trialists (CTT) meta-analysis. METHODS: A simple
Markov model comparing the incremental cost-effectiveness for
two lipid-lowering therapies was developed using TreeAge® soft-
ware. The addition of ezetimibe to simvastatin 40 mg was com-
pared to doubling the simvastatin 40 mg dose from the UK health
plan perspective. Patients enter the model as a primary or sec-
ondary CHD prevention patient. Patients experience a fatal or
non-fatal CHD event, die from another cause, or remain event-
free in each annual cycle. Transition probabilities were deter-
mined by a patient’s baseline risk, age and LDL-C reduction.
Lipid therapy was assumed to provide a 23% reduction in major
coronary events for 1 mmol/L reduction in LDL-C. Costs and
utilities for health states were adapted from the NICE report on
statin therapies and were discounted at 3.5%. Base case analy-
ses were performed for a 55 year old individual, with or without
a history of CHD, annual CHD risk of 3%, and a baseline LDL-
C value of 4 mmol/L. Probabilistic sensitivity analysis (PSA) was
performed and acceptability curves were generated. RESULTS:
The incremental cost per QALY gained of simvastatin/ezetimibe
co-administration was estimated at ≤14,618 and ≤18,549 for
those with and without a history of CHD, respectively. PSA
based upon 10,000 iterations suggest that the ezetimibe co-
administration was below a threshold of ≤30,000/QALY gained
in over 95% of the simulations. Additional analyses suggest that
cost effectiveness of the addition of ezetimibe improves relative
to doubling of statin dose with increasing baseline CHD risk
and/or LDL-C levels. CONCLUSION: The model developed
provides a simple method to compare two treatments based on
their effects on LDL-C. Although the model has several simpli-
fying assumptions it provided results consistent with other CHD
models.
PCV23
EVALUATION OF DYSLIPIDEMIA THERAPIES FOR TREATMENT
OF LOW HDL AND HIGH LDL:A COST-EFFECTIVENESS
ANALYSIS BASED ON NATIONAL HEALTH AND NUTRITION
EXAMINATION SURVEY III
Malone DC1, Charland SL2
1University of Arizona,Tucson, AZ, USA, 2Kos Pharmaceuticals, Inc,
Cranbury, NJ, USA
OBJECTIVES: Cholesterol management guidelines recommend
management of elevated low-density cholesterol (LDL-C) fol-
lowed by management of low high-density cholesterol (HDL-C)
and elevated triglycerides in patients with dyslipidemia. The
objective of this study was to conduct a population-based 
cost-efﬁcacy analysis of dyslipidemic agents using data from 
the National Health and Nutrition Examination Survey III
(NHANES III). METHODS: A 6-month, cost-effectiveness
analysis, from a MCO perspective, incorporating dose escalation
and adverse drug effects (ADEs) associated with pravastatin,
simvastatin, ezetimibe/simvastatin, and extended release (ER)
niacin/lovastatin was conducted. Patients with high LDL-C and
low HDL-C from NHANES III were included to estimate pop-
ulation values for lipids, while product labeling was used 
for lipid changes. Goals for LDL-C were <100 mg/dL and 
<130 mg/dL based on cardiovascular risk; and, HDL-C > 40 or
50 mg/dL (males and females, respectively). Medication (WAC),
physician ofﬁce visits, and laboratory costs (Medicare’s
allowance fees) were included. Monte Carlo simulations were
conducted for probabilistic sensitivity analyses testing key
assumptions of drug efﬁcacy, ADEs, and costs. RESULTS: Rates
of lipid goal achievement was a function of sex, age and treat-
ment. Accounting for dosing and ADEs, the lowest cost for 180
days of treatment was ezetimibe/simvastatin ($561), followed by
ER niacin/lovastatin ($655), pravastatin ($698), and simvastatin
($742). Attainment of LDL-C and HDL-C goals was highest for
ER niacin/lovastatin (77.8%), followed by for ezetimibe/simvas-
tatin (50.1%), simvastatin (44.2%) and pravastatin (29.5%).
Cost/patient achieving combined goals was $842 for ER
niacin/lovastatin, $1120 for ezetimibe/simvastatin, $1677 for
simvastatin, and $2364 for pravastatin. Both pravastatin and
simvastatin were dominated by ezetimibe/simvastatin, while the
incremental cost-effectiveness for ER niacin/lovastatin at $341
per additional patient reaching goal was on the cost-effective
frontier. CONCLUSION: This analysis suggests among patients
with high LDL-C and low HDL-C treatment with ezetimibe/sim-
vastatin and ER niacin/lovastatin are cost-effective strategies
compared to either pravastatin or simvastatin.
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OBJECTIVES: To estimate the cost per patient successfully
treated to NCEP ATP-III goal with high-potency statins or
statin/combinations. METHODS: We constructed a decision
analytic model (from the payer perspective) comparing four
statins or statin combinations: atorvastatin (40–80 mg), rosu-
vastatin (10–40 mg), simvastatin/ezetimibe (Vytorin; 10/10–
10/40 mg), and simvastatin 80 mg. Costs were based on best
available Military Health System (MHS) prices, and only
included drug acquisition costs. Monte Carlo methods were used
to generate a distribution of starting LDL values for a hypo-
thetical cohort of 1000 patients. The mean starting LDL was
189.1 (SD = 18.6), with individual patient LDLs normally dis-
tributed. The percentage of patients in each NCEP ATP-III risk
group was: low risk 41% (LDL goal <160 mg/dl), moderate risk
30% (LDL goal <130 mg/dl), high risk 29% (LDL goal <100
mg/dl). Distributions of efﬁcacy values (% LDL reduction) based
on clinical literature were generated for each treatment arm. The
primary outcome was the percentage of patients successfully
treated to individual NCEP ATP-III goals based on starting LDL
